ALTSTATION.IO

Hologic, Inc. (HOLX) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$74.88

Change

+0.23%

Market Cap

$16.72B

Avg Volume

2.8M

Company Overview

Hologic, Inc. develops and sells a range of medical products centered around women’s health. Their offerings include diagnostic tools, medical imaging systems, and surgical products. Key products are the Aptima molecular diagnostic assays for infectious diseases, 3D digital mammography systems for breast cancer screening, and various solutions for gynecological surgeries. Their customer base includes hospitals, clinics, and laboratories globally, all focused on improving healthcare outcomes for women.

Hologic is a prominent player in the women’s health segment, often seen as a market leader. They hold a competitive edge through their innovative diagnostics and imaging technologies. However, competition from companies like Siemens Healthineers and Siemens, as well as emerging players, poses a constant threat. Regulatory challenges and the need for continual innovation in a rapidly evolving sector add more complexity to their market position.

Currently, Hologic is in a growth phase, leveraging strong demand for their diagnostic products post-COVID-19, particularly in molecular testing. Recent milestones include expansions in their diagnostics segment and increased investments in R&D for new surgical technologies. This strategic focus on advancing women’s health solutions sets the stage for continued revenue growth and market leadership in the coming years.

Key Financials

Market Cap

$16.72B

Revenue

$4.13B

EBITDA

$1.35B

Gross Margin

60.4%

Profit Margin

13.2%

Revenue Growth

2.5%

Total Cash

$2.37B

Total Debt

$2.52B

Free Cash Flow

$848.61M

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

31.07

Forward P/E

15.32

Beta

0.73

52-Week High

$75.36

52-Week Low

$51.90

EPS

$2.41

50-Day Avg

$74.88

200-Day Avg

$68.07

Price/Book

3.18

Technical Analysis

Over the past 52 weeks, Hologic, Inc. (HOLX) has demonstrated a generally bullish trend, seen through a steady increase from a low near $53 in late February to the current price of $74.88. The stock has strong support at approximately $65, highlighted by multiple price rebounds at this level since April. Resistance can be identified around the $75 mark, where the stock has struggled to maintain momentum. Recently, the stock has shown upward momentum, particularly over the last few weeks, with consistent buying pressure pushing prices near this resistance level. The current price sits just below the high end of its 52-week range of approximately $53 to $77, implying it is trading near its peak and is poised for potential breakout or consolidation in the near term. The 52-week change of 14.7% reflects solid performance in the context of market trends.

Recent News and Developments

Here’s a summary of the latest news and developments for Hologic, Inc

(HOLX) stock from February 1 to February 7, 2026:

1. Hologic Receives FDA Approval for Expanded HPV Primary Screening

On February 4, 2026, Hologic announced that its Aptima® HPV Assay received FDA approval for clinician-collected HPV primary screening. This expanded indication enhances Hologic’s cervical health portfolio and provides clinicians with more flexibility in cervical cancer screening options. The Aptima HPV Assay is the only FDA-approved mRNA-based test specifically designed to detect infections most likely to lead to cervical cancer.

2. Shareholders Approve Proposed Blackstone and TPG Buyout

Hologic shareholders officially approved the proposed acquisition of the company by affiliates of funds managed by Blackstone Inc. and TPG Global, LLC on February 5, 2026. This significant vote clears a key shareholder hurdle for the buyout, which is now anticipated to close in March or April 2026, subject to remaining regulatory approvals and customary conditions.

Market Sentiment and Analyst Recommendations

Bull Case

The FDA approval of Aptima HPV for clinician-collected primary screening is a genuine competitive advantage — Hologic now owns the only mRNA-based cervical cancer screening test with this expanded indication, which should drive adoption across a fragmented market. The Blackstone/TPG buyout at $17.2 billion closing in March or April removes uncertainty and provides a floor for shareholders, while the $76-$78 analyst price target suggests 2-4% upside from current levels. Management is executing in a defensive healthcare space with recurring revenue from diagnostic tests, giving the business inherent stability despite the modest 2.5% revenue growth. The company maintains a strong balance sheet with $2.37 billion in cash against $2.52 billion in debt, providing flexibility. At a 31.07 P/E, Hologic isn’t cheap, but it’s not wildly overvalued for a company with a moat in cervical health diagnostics and expanding screening protocols globally.

Bear Case

The Q1 earnings miss is a red flag that shouldn’t be ignored — revenue came in 3.7% below expectations at $1.05 billion, and EPS collapsed 9.2% year-over-year to $0.79 versus the $1.11 estimate, indicating margin pressure and slowing demand. Revenue growth of just 2.5% is anemic for a company trading at 31x earnings; you’re not getting growth to justify that multiple. The pending acquisition creates a dead-cat holding pattern where institutional investors have no incentive to push the stock higher, meaning the $74.88 price is likely where it stays until close. Diagnostic companies face constant reimbursement pressure and competition from larger players like Abbott and Roche, and Hologic’s narrow product focus on women’s health leaves it vulnerable to disruption. The stock is already near its 52-week high at $74.88, leaving little room for error before a pullback to the $65 support level.

What to Watch

The Blackstone/TPG deal closure in March or April is the immediate catalyst — any regulatory delays or renegotiation of terms would tank the stock below $70. Monitor Q2 fiscal 2026 earnings in late April or May for signs of whether the revenue miss was a one-off or the start of a deceleration trend; the market needs to see a return to 4%+ growth to justify the valuation. Watch adoption metrics for the newly approved Aptima HPV assay in clinician-collected settings over the next two quarters — this is the key growth driver that could push the stock above $78. Track reimbursement decisions from major payers on HPV screening protocols, as favorable coverage would expand the addressable market. If the stock breaks above $75.36 (the 52-week high) on volume, it signals institutional conviction ahead of the deal close. Conversely, a drop below $70 would indicate the market is pricing in execution risk or deal skepticism.

Analyst Consensus

HOLD

Based on 10 analyst opinions

Low Target

$76.00

Mean Target

$76.60

High Target

$78.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Instruments & Supplies

Employees

7,070

Earnings & Dividends

Next Earnings

Apr 30, 2026

EPS (Trailing)

$2.41

Dividend Yield

None

Payout Ratio

Frequently Asked Questions

Is HOLX a good stock to buy?

Hologic, Inc. (HOLX) is trading at $74.88 with a P/E of 31.07, which could indicate it’s overvalued based on current earnings. Analysts recommend a HOLD, with a target price of $76.60, suggesting limited upside from current levels. Proceed with caution.

What is HOLX’s price target?

The analyst price target for Hologic is $76.60. Given the current price of $74.88, there is a potential upside of about 2.3%. This makes it less compelling for aggressive investors.

Does HOLX pay a dividend?

No, Hologic does not pay a dividend. This is typical for growth-oriented stocks in the healthcare sector that prefer to reinvest earnings for expansion rather than return cash to shareholders.

What is the 52-week range of HOLX?

Hologic has a 52-week range of $51.90 to $75.36. Currently, it’s near the upper end of this range. This may indicate resistance around the $75 mark.

How does HOLX’s P/E compare to its forward P/E?

HOLX’s current P/E is 31.07, while its forward P/E is significantly lower at 15.32. This suggests that analysts expect earnings growth in the near future, making the stock potentially more attractive relative to its current valuation.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.